A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Takeda
- Study ID
- NCT05816382
- Phase
- PHASE2/PHASE3
- Status
- Recruiting
Conditions
- Narcolepsy Type 1
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- TAK-861 — DRUGTAK-861 tablets
Study Details
The main aim is to evaluate the safety and tolerability of TAK-861 in participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
Key Dates
- Start date
- Apr 5, 2023
- Status verified
- Mar 2026
- Primary completion
- Feb 28, 2028
- Completion
- Feb 28, 2028
Study Design
- Enrollment
- 500 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: TAK-861In this trial, all participants are on TAK-861 treatment and they can switch to one of the available doses as needed.
Primary Outcome Measure
Number of Participants With at Least One or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From signing the informed consent form up to follow-up of 4 weeks after the last dose (Up to approximately 5 years) ]
Central Contacts
- Takeda Contact+1-877-825-3327
Locations (19)
Find similar trials in Birmingham, AL
By research site
Related Studies
- A Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPHASE2 · Recruiting · Centessa Pharmaceuticals (UK) Limited · Auburn, Alabama
- A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPHASE2/PHASE3 · Recruiting · Alkermes, Inc. · Phoenix, Arizona
- A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic HypersomniaPHASE2 · Recruiting · Centessa Pharmaceuticals (UK) Limited · Auburn, Alabama
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1PHASE3 · Recruiting · Alkermes, Inc. · Los Angeles, California